IP Library › Granted Patent US 12,600,764
Granted Patent B2
US 12,600,764 · App. 17/459,486 · Granted Apr 14, 2026

Antigen-binding proteins targeting coronavirus (COV) variants

Inventors: Binquan Luan (Chappaqua, NY); Leili Zhang (Yorktown Heights, NY); Tien Huynh (Yorktown Heights, NY)
Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
C07K16/1003C07K14/005C07K2317/55C07K2317/56C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,600,764
App. No.
17/459,486
Granted
Apr 14, 2026
Kind
B2
Abstract

Techniques regarding antigen-binding proteins that can bind to CoV (e.g., SARS-CoV-2) variants are provided. For example, one or more embodiments described herein can comprise an antigen-binding protein that can comprise a heavy polypeptide chain variable region with an amino acid sequence that is a variant of SEQ ID NO: 7. The amino acid sequence can comprise at least one amino acid substitution selected from the group consisting of: R50D, R50E, R50W, R50F, R50Y, R50L, R50V, R50I, R50Pho, I54D, I54E, I54W, I54F, I54Y, I54Pho, L55D, L55E, L55W, L55F, L55Y, and L55Pho.

Claims (20)

1 . An antigen-binding protein, comprising:

a heavy polypeptide chain variable region with a first amino acid sequence that comprises SEQ ID NO: 10; and

a light polypeptide chain variable region with a second amino acid sequence that is selected from the first group consisting of SEQ ID NO: 18 and SEQ ID NO: 19.

2 . The antigen-binding protein of claim 1 , wherein the heavy polypeptide chain variable region and the light polypeptide chain variable region have a binding interaction with a portion of a receptor binding domain of a variant of a SARS-CoV-2 spike protein.

3 . The antigen-binding protein of claim 2 , wherein the binding interaction is relative to an amino acid substitution of the receptor binding domain of the variant of the SARS-CoV-2 spike protein.

4 . The antigen-binding protein of claim 3 , wherein the binding interaction comprises formation of a salt-bridge.

5 . The antigen-binding protein of claim 3 , wherein the binding interaction comprises a cation-n interaction.

6 . An antigen-binding protein, comprising:

a heavy polypeptide chain variable region with a first amino acid sequence that comprises SEQ ID NO: 10; and

a light polypeptide chain variable region with a second amino acid sequence that comprises SEQ ID NO: 18.

7 . The antigen-binding protein of claim 6 , wherein the heavy polypeptide chain variable region and the light polypeptide chain variable region have a binding interaction with a portion of a receptor binding domain of a variant of a SARS-CoV-2 spike protein.

8 . The antigen-binding protein of claim 7 , wherein the binding interaction is relative to an amino acid substitution of the receptor binding domain of the variant of the SARS-CoV-2 spike protein.

9 . The antigen-binding protein of claim 8 , wherein the binding interaction comprises formation of a salt-bridge.

10 . An antigen-binding protein, comprising:

a heavy polypeptide chain variable region with a first amino acid sequence that comprises SEQ ID NO: 10; and

a light polypeptide chain variable region with a second amino acid sequence that comprises SEQ ID NO: 19.

11 . The antigen-binding protein of claim 10 , wherein the heavy polypeptide chain variable region and the light polypeptide chain variable region have a binding interaction with a portion of a receptor binding domain of a variant of a SARS-CoV-2 spike protein.

12 . The antigen-binding protein of claim 11 , wherein the binding interaction is relative to an amino acid substitution of the receptor binding domain of the variant of the SARS-CoV-2 spike protein.

13 . The antigen-binding protein of claim 11 , wherein the binding interaction comprises formation of a salt-bridge.

14 . The antigen-binding protein of claim 11 , wherein the binding interaction comprises a cation-π interaction.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2021
From: LUAN, BINQUAN; ZHANG, LEILI; HUYNH, TIEN
To: INTERNATIONAL BUSINESS MACHINES CORPORATION
Reel/Frame 057312/0865 →
Continuity (1)
Related Publication 20230073821A1 · Mar 9, 2023
References Cited (39)
US 10954289B1 · Babb et al. · 2021 [cited by applicant]
US 20090137002A1 · Petrul · 2009 [cited by examiner]
US 20210070887A1 · Ambrogelly et al. · 2021 [cited by applicant]
US 20210269520A1 · Allan · 2021 [cited by examiner]
US 20210292393A1 · Westendorf et al. · 2021 [cited by applicant]
CN 11349150B · 2020 [cited by applicant]
WO WO2011140151A1 · 2011 [cited by examiner]
WO 2017147293A1 · 2017 [cited by applicant]
WO 2019224717A2 · 2019 [cited by applicant]
WO 2019224718A2 · 2019 [cited by applicant]
WO WO2021163031A1 · 2021 [cited by examiner]
WO WO2021183195A1 · 2021 [cited by examiner]
WO WO2021183359A1 · 2021 [cited by examiner]
WO 2023026246A1 · 2023 [cited by applicant]
Sela-Culang (Frontiers in Immunology (2013) 4: 302) (Year: 2013). [cited by examiner]
Genheden (Expert Opinion Drug Discovery (2015) 10(5): 449-461) (Year: 2015). [cited by examiner]
Dondelinger (Frontiers in Immunology (2018) 9: 2278) (Year: 2018). [cited by examiner]
Almagro (Frontiers in Immunology (2018) 8: 1751) (Year: 2018). [cited by examiner]
“P01861—IGHG4_HUMAN” entry on Uniprot. Sequence of “P01861-2” (v2) last updated on May 3, 2023. Accessed at <https://www.uniprot.org/uniprotkb/P01861/entry> on Apr. 22, 2025. (Year: 2023). [cited by examiner]
Ni (The Protein Journal (2024) 43: 683-696) (Year: 2024). [cited by examiner]
Liu (MAbs (2021) 13(1): e1919285) (Year: 2021). [cited by examiner]
B. Luan and T. Huynh, “Insights on SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival,” bioRxiv, Posted Feb. 7, 2021, https://doi.org/10.1101/2021.02.06.430088. [cited by applicant]
B. Jones et al., “The neutralizing antibody, LY-CoV555, protects against SARS-COV-2 infection in non-human primates,” Science Translational Medicine, Apr. 5, 2021. doi: 10.1126/scitranslmed.abf1906. [cited by applicant]
K. Westendorf et al., “LY-CoV1404 potently neutralizes SARS-CoV-2 variants,” bioRxiv, Posted May 4, 2021, https://doi.org/10.1101/2021.04.30.442182. [cited by applicant]
S. Robinson et al., “Epitope profiling of coronavirus-binding antibodies using computational structural modelling,” bioRxiv, Posted Apr. 12, 2021. [cited by applicant]
H. Cho et al., “Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants,” bioRxiv, Posted Apr. 1, 2021, https://doi.org/10.1101/2021.04.01.437942. [cited by applicant]
P. Taylor et al., “Neutralizing monoclonal antibodies for treatment of COVID-19.” Nat Rev Immunol, 2021. https://doi.org/10.1038/s41577-021-00542-x. [cited by applicant]
L.G. Abinader (Oct. 28, 2020) U.S. Government funding of Lilly's LY-CoV555 antibody against COVID-19. Knowledge Ecology International. https://www.keionline.org/34308. [cited by applicant]
U.S. Food & Drug Administration (Apr. 16, 2021) Coronavirus (COVID-19) Update: FDA Revokes Emergency use Authorization for Monoclonal Antibody Bamlanivimab. https://www.fda.gov/news-events/press-announcements/coronaviru… [cited by applicant]
T. Starr et al.; “Complete map of SARS-CoV-2 RBD mutationsthat escape the monoclonal antibodyLY-CoV555 and its cocktail with LY-CoV016”. Cell Report Medicine, 2, 100255, 2021. [cited by applicant]
T. Tada et al.; “Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies”. bioRxiv, doi: https://doi.org/10.1101/2021.02.18.431897. [cited by applicant]
J. Villar et al.; “Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial”. The Lancet Respiratory Medicine 2020, 8, 267-276. [cited by applicant]
J. Beigel et al.; “Remdesivir for the treatment of Covid-19—preliminary report”. New England Journal of Medicine 2020. [cited by applicant]
L. Piroth et al.; “Comparison of the Characteristics, Morbidity, and Mortality of COVID-19 and Seasonal Influenza: a Nationwide, Population-Based Retrospective Cohort Study”. Lancet Respir. Med. 2020, 9, 251-259. [cited by applicant]
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCOV and Naming it SARS-CoV-2. Nat. Microbio. 2020, 5,… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2022/058006 dated Dec. 1, 2022. [cited by applicant]
Liu, et al., “Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda,” J. Chem. Inf. Model. Oct. 14, 2021, 61, 5133-5140, https://doi.org/10.1021/acs.jcim.1c01058. [cited by applicant]
Zhang, et al., “in silico Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617,” May 14, 2021, Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv, doi: https://doi… [cited by applicant]
Jones et al., “LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection”, Science Translational Medicine, Oct. 9, 2020, 29 pages. [cited by applicant]